Financial statements Europharma Research & Science Center
Balance sheet data of EUROPHARMA RESEARCH & SCIENCE CENTER
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Total assets | 5 625 168,58 | 5 294 721,72 | 4 275 781,05 | 5 283 392,96 | 4 098 546,12 | 3 870 390,85 |
| A. Fixed assets | 816 036,45 | 710 619,86 | 1 226 328,56 | 1 627 548,12 | 1 772 158,96 | 1 793 062,80 |
| B. Current assets | 4 809 132,13 | 4 584 101,86 | 3 049 452,49 | 3 655 844,84 | 2 326 387,16 | 2 077 328,05 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 5 625 168,58 | 5 294 721,72 | 4 275 781,05 | 5 283 392,96 | 4 098 546,12 | 3 870 390,85 |
| A. Equity | 2 790 125,72 | 3 349 551,63 | 1 042 181,89 | 1 885 286,50 | 2 467 486,25 | 2 915 917,18 |
| B. Liabilities and provisions for liabilities | 2 835 042,86 | 1 945 170,09 | 3 233 599,16 | 3 398 106,46 | 1 631 059,87 | 954 473,67 |
| I. Long-term liabilities | 0,00 | 0,00 | 866 110,50 | 72 175,86 | 0,00 | 0,00 |
| II. Short-term liabilities | 2 810 841,01 | 1 921 796,24 | 2 364 176,66 | 3 323 446,60 | 1 629 403,87 | 953 645,67 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.